دورية أكاديمية
أعرض في EDS

Plasma osteopontin in persons with HIV and the risk for cardiovascular disease.

التفاصيل البيبلوغرافية
العنوان: Plasma osteopontin in persons with HIV and the risk for cardiovascular disease.
المؤلفون: Masenga SK; HAND Research group, School of Medicine and Health Sciences, Mulungushi University, Livingstone, Zambia., Romanelli A; Department of Anaesthesia and Intensive Care, University Hospital 'San Giovanni di Dio e Ruggi D'Aragona', Salerno, Campania, Italy., Kooij KW; British Columbia Centre for Excellence in HIV/AIDS, Vancouver.; Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.
المصدر: AIDS (London, England) [AIDS] 2023 Feb 01; Vol. 37 (2), pp. 355-357.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 8710219 Publication Model: Print Cited Medium: Internet ISSN: 1473-5571 (Electronic) Linking ISSN: 02699370 NLM ISO Abbreviation: AIDS Subsets: MEDLINE
أسماء مطبوعة: Publication: 1998- : London, England : Lippincott Williams & Wilkins
Original Publication: London : Gower Academic Journals, c1987-
مواضيع طبية MeSH: Cardiovascular Diseases*/epidemiology , HIV Infections*/complications, Humans ; Osteopontin ; Risk Factors ; Biomarkers
References: Mayeux R. Biomarkers: potential uses and limitations . NeuroRx 2004; 1:182–188.
Justice AC, Erlandson KM, Hunt PW, Landay A, Miotti P, Tracy RP. Can biomarkers advance HIV research and care in the antiretroviral therapy era? . J Infect Dis 2018; 217:521–528.
Wang KX, Denhardt DT. Osteopontin: role in immune regulation and stress responses . Cytokine Growth Factor Rev 2008; 19:333–345.
Icer MA, Gezmen-Karadag M. The multiple functions and mechanisms of osteopontin . Clin Biochem 2018; 59:17–24.
Zhu Z, He Y, Shi M, Guo D, Zhang K, Ren L, et al. Plasma osteopontin levels and adverse clinical outcomes after ischemic stroke . Atherosclerosis 2021; 332:33–40.
Maleš J, Mihalj H, Šestak A, Kralik K, Smolić M. Osteopontin levels in patients with squamous metastatic head and neck cancer . Medicina (Kaunas) 2021; 57:185.
Larsson A, Helmersson-Karlqvist J, Lind L, Ärnlöv J, Feldreich TR. Strong associations between plasma osteopontin and several inflammatory chemokines, cytokines, and growth factors . Biomedicines 2021; 9:908.
Gao N, Zhang-Brotzge X, Wali B, Sayeed I, Chern JJ, Blackwell LS, et al. Plasma osteopontin may predict neuroinflammation and the severity of pediatric traumatic brain injury . J Cereb Blood Flow Metab 2020; 40:35–43.
Li H-J, Han N-N, Nan Y, Zhang K, Li G, Chen H. Plasma osteopontin acts as a prognostic marker in acute intracerebral hemorrhage patients . Clin Chim Acta 2020; 500:208–212.
Chai YL, Chong JR, Raquib AR, Xu X, Hilal S, Venketasubramanian N, et al. Plasma osteopontin as a biomarker of Alzheimer's disease and vascular cognitive impairment . Sci Rep 2021; 11:4010.
Podzimkova J, Palecek T, Kuchynka P, Marek J, Danek BA, Jachymova M, et al. Plasma osteopontin levels, but not its myocardial expression, reflect heart failure severity in recently diagnosed dilated cardiomyopathy . Herz 2020; 45:105–110.
Varalakshmi B, Kiranmyai VS, Aparna B, Ram R, Rao PVLNS, Kumar VS. Plasma osteopontin levels in patients with acute kidney injury requiring dialysis: a study in a tertiary care institute in South India . Int Urol Nephrol 2020; 52:917–921.
Wang C, He M, Peng J, Li S, Long M, Chen W, et al. Increased plasma osteopontin levels are associated with nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus . Cytokine 2020; 125:154837.
Bruha R, Vitek L, Smid V. Osteopontin - a potential biomarker of advanced liver disease . Ann Hepatol 2020; 19:344–352.
Burdo TH, Lo J, Abbara S, Wei J, DeLelys ME, Preffer F, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients . J Infect Dis 2011; 204:1227–1236.
Chagan-Yasutan H, Saitoh H, Ashino Y, Arikawa T, Hirashima M, Li S, et al. Persistent elevation of plasma osteopontin levels in HIV patients despite highly active antiretroviral therapy . Tohoku J Exp Med 2009; 218:285–292.
Burdo TH, Ellis RJ, Fox HS. Osteopontin is increased in HIV-associated dementia . J Infect Dis 2008; 198:715–722.
Strimbu K, Tavel JA. What are biomarkers? . Curr Opin HIV AIDS 2010; 5:463–466.
Shirakawa K, Sano M. Osteopontin in cardiovascular diseases . Biomolecules 2021; 11:1047.
Robinson J, Toribio M, Quinaglia T, Awadalla M, Talathi R, Durbin C, et al. Plasma osteopontin relates to myocardial fibrosis and steatosis and to immune activation among women with HIV . AIDS 2023; 37:305–310.
Agarwal N, Ramirez Bustamante CE, Wu H, Armamento-Villareal R, Lake JE, Balasubramanyam A, et al. Heightened levels of plasma growth differentiation factor 15 in men living with HIV . Physiol Rep 2022; 10:e15293.
Toribio M, Neilan TG, Awadalla M, Stone LA, Rokicki A, Rivard C, et al. Intramyocardial triglycerides among women with vs without HIV: hormonal correlates and functional consequences . J Clin Endocrinol Metab 2019; 104:6090–6100.
Royston L, Isnard S, Perrin N, Sinyavskaya L, Berini C, Lin J, et al. Growth differentiation factor-15 as a biomarker of atherosclerotic coronary plaque: value in people living with and without HIV . Front Cardiovasc Med 2022; 9:964650.
Hsue PY. Mechanisms of cardiovascular disease in the setting of HIV infection . Can J Cardiol 2019; 35:238–248.
Raghavan A, Rimmelin DE, Fitch KV, Zanni MV. Sex differences in select noncommunicable HIV-associated comorbidities: exploring the role of systemic immune activation/inflammation . Curr HIV/AIDS Rep 2017; 14:220–228.
Kentoffio K, Temu TM, Shakil SS, Zanni MV, Longenecker CT. Cardiovascular disease risk in women living with HIV . Curr Opin HIV AIDS 2022; 17:270–278.
Zanni MV, Awadalla M, Toribio M, Robinson J, Stone LA, Cagliero D, et al. Immune correlates of diffuse myocardial fibrosis and diastolic dysfunction among aging women with human immunodeficiency virus . J Infect Dis 2020; 221:1315–1320.
Ghosh D, Poisson LM. Omics’ data and levels of evidence for biomarker discovery . Genomics 2009; 93:13–16.
معلومات مُعتمدة: K23 HL147799 United States HL NHLBI NIH HHS; P30 AI060354 United States AI NIAID NIH HHS; T32 MH079785 United States MH NIMH NIH HHS; R01 HL146267 United States HL NHLBI NIH HHS; R01 HL137562 United States HL NHLBI NIH HHS
سلسلة جزيئية: ClinicalTrials.gov NCT02874703
المشرفين على المادة: 106441-73-0 (Osteopontin)
0 (Biomarkers)
تواريخ الأحداث: Date Created: 20221221 Date Completed: 20221222 Latest Revision: 20230228
رمز التحديث: 20230228
DOI: 10.1097/QAD.0000000000003445
PMID: 36541647
قاعدة البيانات: MEDLINE
الوصف
تدمد:1473-5571
DOI:10.1097/QAD.0000000000003445